Beyond BCG: What Comes Next for Patients

In this episode of Bladder Cancer Matters, host and survivor Rick Bangs sits down with ImmunityBio's Chief Medical Officer, Dr. Bobby Reddy, for a fascinating, hopeful look at the future of bladder cancer treatment. They unpack how next-generation immunotherapies like ANKTIVA—paired with innovative approaches to BCG—are reshaping care for patients, especially those with limited options, while also tackling real-world challenges like ongoing BCG shortages. Dr. Reddy breaks down the science in a way that's accessible, highlighting how activating the body's own immune system could lead to longer-lasting responses and even help patients avoid more invasive treatments. Tune in to this conversation about progress and possibility.